A phase I trial of the anti-CTLA-4 antibody ipilimumab in heavily pretreated paediatric patients with relapsed or refractory disease yielded stable disease in two of the eight osteosarcoma patients involved in the trial, suggesting moderate activity [204]. Here, CTLA4 is linked to osteosarcoma.